12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ReZolve2: Pivotal trial started

Reva began the international pivotal RESTORE II trial to evaluate the ReZolve2 stent in up to 125 patients.

Reva Medical Inc. (ASX:RVA), San...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >